Home › Compare › BXRX vs O

BXRX vs O: Dividend Comparison 2026

BXRX yields 9174.31% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXRX wins by $23597687873458488.00M in total portfolio value
10 years
BXRX
BXRX
● Live price
9174.31%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23597687873458488.00M
Annual income
$23,102,328,897,111,608,000,000.00
Full BXRX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — BXRX vs O

📍 BXRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXRXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXRX + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BXRX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXRX
Annual income on $10K today (after 15% tax)
$779,816.51/yr
After 10yr DRIP, annual income (after tax)
$19,636,979,562,544,865,000,000.00/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, BXRX beats the other by $19,636,979,562,544,865,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXRX + O for your $10,000?

BXRX: 50%O: 50%
100% O50/50100% BXRX
Portfolio after 10yr
$11798843936729244.00M
Annual income
$11,551,164,448,555,804,000,000.00/yr
Blended yield
97.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

BXRX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-15.9
Piotroski
1/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXRX buys
0
O buys
0
No recent congressional trades found for BXRX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXRXO
Forward yield9174.31% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$23597687873458488.00M ✓$34.2K
Annual income after 10y$23,102,328,897,111,608,000,000.00 ✓$5,098.20
Total dividends collected$23564675825677336.00M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: BXRX vs O ($10,000, DRIP)

YearBXRX PortfolioBXRX Income/yrO PortfolioO Income/yrGap
1← crossover$928,131$917,431.19$10,818$607.86+$917.3K → BXRX
2$80,572,213$79,579,112.81$11,786$741.30+$80.56M → BXRX
3$6,542,624,325$6,456,412,056.54$12,944$910.50+$6542.61M → BXRX
4$496,975,869,083$489,975,261,055.26$14,343$1,127.28+$496975.85M → BXRX
5$35,315,297,301,597$34,783,533,121,678.35$16,053$1,408.17+$35315297.29M → BXRX
6$2,347,816,625,029,715$2,310,029,256,917,006.50$18,167$1,776.65+$2347816625.01M → BXRX
7$146,039,627,186,550,560$143,527,463,397,768,750.00$20,815$2,266.60+$146039627186.53M → BXRX
8$8,499,944,982,314,035,000$8,343,682,581,224,426,000.00$24,179$2,927.66+$8499944982314.01M → BXRX
9$462,952,314,342,881,700,000$453,857,373,211,805,700,000.00$28,521$3,833.95+$462952314342881.69M → BXRX
10$23,597,687,873,458,490,000,000$23,102,328,897,111,608,000,000.00$34,218$5,098.20+$23597687873458488.00M → BXRX

BXRX vs O: Complete Analysis 2026

BXRX — Stock

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Full BXRX Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this BXRX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXRX vs SCHDBXRX vs JEPIBXRX vs KOBXRX vs MAINBXRX vs STAGBXRX vs ADCBXRX vs NNNBXRX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.